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Answer or Anguish?
improvement perceived. Acute toxici-
ties, in fact, can worsen the clinical con-
dition especially when receiving MV 
and also reduces the quality of life. We 
would like to know whether the authors 
would have considered any pre- and 
post-RT pulmonary assessment/func-
tion studies. In this study, the authors do 
not provide information on acute car-
diopulmonary toxicities related to RT.4
Third, we would like the authors 
to comment on any variables they 
had noted or would have preferred to 
measure that could predict the risk of 
toxicity and outcome in their patient 
population.
Fourth, although a small number 
of patients were successfully extubated 
and discharged out of intensive care unit 
and hospital, it would have been useful 
to understand their quality of life, per-
formance scores, and ability to perform 
activities of daily living. This may shift 
the focus from extubation from MV to 
postextubation meaningful lifestyle.
Finally, information on end-
of-life care issues in their patient 
population and mode of MV, such as 
single lung versus double lung, pressure 
cycled versus volume cycled, and stan-
dard versus high-frequency ventilation, 
would have addressed some practical 
issues for clinicians and intensivist.5
We believe that further clinical 
studies will provide more understand-
ing of the role of RT in MAO requir-
ing MV. This study has indeed paved 
the way to this understanding and we 
would like to commend the authors for 
this work.
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To the Editor:
Critically ill cancer patients with 
respiratory failure due to malignant 
airway obstruction (MAO) and need-
ing mechanical ventilation (MV) pose a 
challenge and a controversy in clinical 
management for the intensivist.1 In some 
instances, difficult extubation from MV 
require palliative radiation therapy (RT) to 
relieve symptoms and facilitate weaning 
from MV. Although MAO-related acute 
respiratory failure resulting in MV is an 
infrequent presentation, RT can aid in the 
liberation from MV and provide a safe 
alternative before the situation worsens 
leading to prolonged MV and worsening 
of signs and symptoms. This approach, 
however, is not widely practiced and is 
still debated among clinicians.
We read with interest the retrospec-
tive study by Louie et al.2 which showed 
that 27% of patients were successfully 
extubated after RT and six of seven 
patients were successfully discharged 
home. We would like to bring certain prac-
tical issues that need to be considered.
First, short-course palliative RT 
of 30 Gy has been shown to achieve 
adequate reduction in symptoms due to 
airway stenosis without severe acute tox-
icities.3 In this study, the patients received 
lower dose of radiation. It is possible that 
more patients could have benefited with a 
higher dose of palliative RT with an even 
better outcome than reported.
Second, pulmonary and cardiac 
toxicities are a concern with RT to 
the chest. The degree of toxicity pre-
dicted needs to be balanced with the 
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In Response:
We would like to thank Dr. 
Esquinas and Dr. Pravinkumar for their 
insightful comments on our work. Our 
goal was to raise awareness of radio-
therapy as a treatment modality for 
severe malignant airway obstruction, 
necessitating intubation and mechani-
cal ventilation, and we are glad the arti-
cle has provoked discussion.
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Palliative thoracic radiother-
apy is a cornerstone of any radiation 
oncology practice; older estimates 
from the United Kingdom suggest 
that 10% to 25% of a typical radia-
tion oncologist’s practice deals with 
lung-related issues, with a high pro-
portion of these palliative in nature.1 
A meta-analysis and guideline-based 
recommendations indicate that higher 
doses of palliative radiotherapy (such 
as 30 Gy in 10 fractions) translate to 
a modest benefit in overall survival 
when compared with lower biological 
effective dose regimens.2,3 Although it 
is difficult to retrospectively analyze 
the decision making in cases where 
lower doses of radiotherapy were 
used in our study, we do note that 
approximately half of patients (48%) 
received at least 20 Gy. From a prac-
tical point of view, a careful balance 
must be struck between the urgency 
of treatment and the ability to deliver 
higher doses of radiotherapy safely. 
Common palliative dose fractionation 
schemes (such as 8, 20, or 30 Gy in 1, 
5, and 10 fractions, respectively) can 
be planned and delivered on the same 
day as consultation. Conversely, any 
benefit in local control derived from 
higher doses, using intensity-modu-
lated radiotherapy or image-guided 
radiotherapy approaches, may be miti-
gated by delays incurred in a lengthier 
treatment-planning process.
Severe malignant airway obstruc-
tion can present dramatically and result 
in acute dyspnea and respiratory col-
lapse. Often these patients are urgently 
intubated and only afterward questions 
surrounding best management, includ-
ing a reasonable duration of trialing 
mechanical ventilation arise. We con-
sidered abstracting ventilation data, but 
ventilation strategies often changed dur-
ing treatment and were heterogenous. As 
with any intervention where the primary 
goal is palliation, assuring that functional 
status is improved by the intervention is 
paramount. Although we did not directly 
abstract quality of life or performance 
status data, the fact that approximately 
all extubated patients were discharged 
home, with some receiving chemother-
apy thereafter, can be considered surro-
gates of their improved functional status.
Although a randomized con-
trol trial to demonstrate the efficacy 
of radiotherapy over best supportive 
care in this patient population would 
be ideal, given these patients’ grave 
clinical situation and the suggestion 
that radiotherapy could be of benefit, 
it would be difficult to establish equi-
poise to run such a trial. Going for-
ward, we propose that institutions using 
radiotherapy in this setting develop 
guidelines with input from oncologists, 
intensivists, and allied health profes-
sionals. Just as important as identifying 
endpoints relevant to each multidisci-
plinary stakeholder, a guideline would 
set standards and policies to improve 
patient safety during transportation 
and minimize the time away from the 
intensive care unit. Although data from 
such an initiative would be intriguing, 
in the interim we would encourage oth-
ers to report their experience in using 
radiotherapy in this clinical setting or 
to discuss obstacles that currently pre-
vent them from doing so.
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To the Editor:
A 50-year-old asian man with a 
remote history of light smoking (half 
a pack per day × 4 years) presented 
to the orthopedic clinic with several 
months of progressively worsening 
right hip pain. A radiograph showed 
a lytic lesion in the right acetabu-
lum with soft-tissue involvement. 
Computed topography (CT)-guided 
biopsy revealed a moderately differ-
entiated adenocarcinoma, positive 
for TTF-1 and CK7 and negative for 
CK20 by immunohistochemistry. CT 
scan revealed a 10 mm irregular nodule 
in the apex of the left lung with hilar 
and mediastinal lymphadenopathy. 
The patient was diagnosed with meta-
static lung adenocarcinoma and staged 
as IVB. EGFR mutation  analysis 
was performed using  massively 
parallel sequencing using the Ion 
AmpliSeq Cancer Hotspot Panel v2 
(Life Technologies, Carlsbad, CA). 
A compound heterozygous mutation 
in exon 19 (c.2240T>C, p.L747S and 
c.2246_2260de15, p.A750_K754del) 
was identified (Fig. 1) and the result 
was confirmed by Sanger sequenc-
ing (Fig. 2). The two mutations were 
also found to be allelic as shown in 
Figure 1. Given the positive family his-
tory of lung cancer (father; no detailed 
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